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Abstract: With the increase in the number of lung transplants, it is
expected that there will be a corresponding increase in the number
of lung cancers reported in these patients. Longevity of the trans-
plant recipients, lung transplantation for chronic obstructive pulmo-
nary disease and idiopathic pulmonary fibrosis, a history of smok-
ing, and the increasing age of the lung donors make lung cancer
more likely. Nodules and masses seen in chest imaging in lung
transplant patients call for work up until a final diagnosis is achieved
because there is a high likelihood of a serious infection or malignancy.
The presence of a native lung is a major risk factor for lung cancer
occurring in the transplant setting. Lung cancer of donor origin is rare.
Bronchioloalveolar carcinoma confined to one lung can potentially be
treated by transplanting the affected lung. Treatment for patients with
lung cancer in the lung transplant setting has to be individualized
because of the complexity of their medical problems and multiple
medications. Attention needs to be focused on detecting lung cancer
early in these patients to achieve a favorable outcome.
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Lung transplantations are being done in much larger num-bers since the first successful procedure in 1983.1 In the
year 2005 alone, 1530 lung transplants were performed in
North America. The major indications for transplantation are
emphysema or chronic obstructive pulmonary disease (COPD)
in 29% of patients receiving a transplanted lung, and idiopathic
pulmonary fibrosis (IPF) in 24.4%. The 3-year survival after
lung transplantation is now approximately 65%.2 Immuno-
suppression after solid organ transplant may increase the
overall risk for malignancy because of decreased immune
surveillance. Data from the Cincinnati transplant registry
show a 3- to 4-fold increase in cancer in immunosuppressed
organ allograft recipients. The statistics display a strikingly
increased incidence of skin cancers, cancers of the lip, cer-
vical intraepithelial neoplasia, vulval and vaginal carcinomas,
Kaposi sarcoma, renal cell carcinomas, hepatocellular carci-
nomas, and non-Hodgkin’s lymphomas. However, the inci-
dence of common malignancies, such as carcinomas of lung,
breast, or colon, was not particularly increased.3 This sce-
nario is likely to change with the changing profiles of both
recipients and organ donors. COPD and IPF as major indi-
cations for transplantation lead to the presence of a pool of
recipients with a higher baseline risk of developing lung
carcinoma. The association of lung cancer and IPF has been
reviewed in several excellent reviews.4–6 While there is some
controversy about the pathogenesis and causation of lung
cancer in patients with IPF. The lowest reported prevalence
rates were in studies based on review of death certificates
with the attendant risks of under–reporting.7,8 This risk is not
completely eliminated with lung transplantation, especially in
those patients who receive a single lung transplant and have
a native lung in situ. The increasing demand for donor organs
implies that there are donors who are older and have a history
of smoking again increasing the risk of developing broncho-
genic carcinoma after lung transplantation. This review will
outline the risks, epidemiology, and prognosis of lung cancer
associated with lung transplantation.
SEARCH STRATEGY
Search terms used were “Lung Cancer” and “Lung
Transplantation” as key words in Ovid medline with no date
limits. Search terms in Pubmed were “Lung Cancer AND
Lung Transplantation.” Case series of lung cancers in lung
transplant patients were manually identified from the search
results.
Bronchogenic Carcinoma in the Native Lung
after Single Lung Transplantation
There seems to be a gradual increase in the number of
patients with lung transplant reported to have bronchogenic
carcinoma more than the last two decades. In a single insti-
tution review of 219 patients treated from 1987 to 1997, a
single squamous cell carcinoma of the lung was reported
from a total of 13 malignancies in 9 of the 219 lung transplant
patients (0.46%).9 In a similar manner, another retrospective
study reviewing heart and lung transplant patients at an
institution from 1968 to 1997 found only a single squamous
cell lung cancer in the native lung of a patient with IPF out of
99 patients who survived the first month after transplanta-
tion.10 Another report showed a slightly increased incidence
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of lung cancer in a series of patients transplanted from 1991
to 2000. Six of the 251 (2.4%) patients who received lung
transplants developed lung cancer.11 Another retrospective
review of 396 patients who received lung transplants between
1985 and 2001 found one lung cancer (0.25%); genotyping of
the tumor revealed it to be of donor origin.12 In a larger
analysis of 2168 patients from seven centers, 24 lung cancers
(1%) were recorded, all in the native lung. This study re-
viewed patients who underwent single lung, bilateral lung, or
heart lung transplants from 1981 to 2001 and survived be-
yond 1 month. The frequency of bronchogenic carcinoma in
patients who had unilateral lung transplantation was 2%.13
Finally, Dickson et al. compared 131 consecutive single lung
transplant recipients to 131 matched bilateral lung transplant
recipients who were transplanted between 1992 and 2005. Of
the single lung transplant recipients, 6.9% developed primary
lung cancer, whereas none of the bilateral lung transplant
recipients developed lung cancer.14 In the current decade,
there seems to be a gradual increase in the rate of lung cancer
in patients after lung transplantation (Table 1).
This subtle upward trend in the reported incidence of
lung cancer in single center and multicenter studies is likely
related to a variety of factors including some of the following.
Y Longer survival of transplant recipients:
The average death rate in the first year after trans-
plantation came down from 290 per 1000 patient years at
risk to 169 per 1000 patient years at risk in 2004. The Lung
Allocation Score (LAS) system was introduced in May
2005 and an increase in death rates to 200 per 1000
patient years was noticed in 2005 likely because of
sicker patients being given priority in the new system
rather than the time on the transplant list.15 The latest
ISHLT transplant registry data report a 1-year survival of
82.3% reflecting a continuing improvement in survival.2
Improvements in survival noted in the most recent years
have been concentrated in the first 3 months after trans-
plantation. This likely reflects improvements in surgical
techniques and early complications rather than improve-
ments in management of late complications like chronic
rejection.16
Y Effect of immunosuppressive therapies:
The influence of immunosuppression as an etio-
logical factor for the development of malignancy is
discussed later in the article.
Y Proportion of patients receiving transplants for COPD
and IPF:
There has been an increase in the proportion of lung
transplantations performed for pulmonary fibrosis and a
concomitant decrease in the proportion of patients with
COPDwho received lung transplants with the institution of
the LAS system. However, these two diagnoses still ac-
count for the majority of transplants performed.15,17
Y Increasing age of the donor pool:18,19
With the increasing demand for organs for lung
transplantation, international recommendations now al-
low the use of donors who are older than 60.18,19
Incidence of smoking in both donors and recipients.
Incidence of smoking in both donors and recipients.
All of the studies summarized in Table 1 report cancer
occurring in the native lung. In fact, the presence of the native
lung was the strongest risk factor for developing lung cancer
after transplantation identified by Dickson et al. The data
from the single institution and multiinstitution studies argue
strongly for smoking as a risk factor for developing lung
cancer after lung transplantation. Not surprisingly, it has been
reported that smoking more than 60 pack-years is a marked
risk factor.14 The widely varying time to detection in these
studies likely reflects the length of follow-up in each study
rather than any identifiable significance in pathogenesis (Ta-
ble 2). Another potential risk factor for lung cancer after lung
TABLE 1. Retrospective Studies of Lung Transplant Patients with Lung Cancer in the Native Lung
Author Institution No. of Patients
No of Patients
with Lung Cancer
in the Native Lung % Pathology
Spiekerkoetter
et al.9
Hannover Medical School,
Germany
219 1 0.46 Squamous cell carcinoma
Choi et al.10 Stanford University 99 1 1.1 Squamous cell carcinoma
Arcasoy et al.11 University of Pennsylvania 251 6 2.4 2 Squamous cell cancers
3 Adenocarcinomas
1 Poorly differentiated ca.
Collins et al.13 7 North American lung
transplantation centers
2168 24 1 8 Squamous cell carcinomas
7 Adenocarcinomas
4 Poorly differentiated NSCLC
1 Each of anaplastic carcinoma,
adenocarcinoma with small cell
component, bronchioalveolar
carcinoma, and carcinosarcoma
de Perrot et al.12 Toronto General hospital 396 1 0.25 Bronchioalveolar carcinoma
Dickson et al.14 Duke University 131 Single lung
transplant patients
9 6.9 6 Squamous cell carcinomas
2 Adenocarcinomas
1 Carcinosarcoma
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transplantation is the presence of posttransplant immunosup-
pression. The most often used immunosuppressive regimen
was cyclosporine, azathioprine, and corticosteroids.9,11–13
The use of increasingly long-term immunosuppression may
lead to higher incidences of cancer in these patients, although
no data are available on the lung cancer risk after different
immunosuppressive regimens for lung transplantation.
Bronchogenic Carcinoma in the Recipient’s
Explanted Lung
Lung cancer in the native lung after lung transplanta-
tion may gradually be on the rise (Table 1). However, the
presence of lung cancer in the explanted lung either known or
surreptitiously found at surgery presents an intriguing clinical
problem as well. Svendsen et al. reported two patients who
underwent single lung transplantation whose explanted lungs
revealed well-differentiated adenocarcinomas less than a cen-
timeter in size. Both these patients did well with the lung
transplantation effectively functioning as a lung resection.20
A retrospective review of 214 consecutive lung transplants
from 1991 to 2004 from the Cleveland Clinic reported four
instances (2%) where lung cancers were found in the ex-
planted lung. There were three adenocarcinomas and one
squamous cell carcinoma. The primary indication for trans-
plant was emphysema in three of the patients and IPF in the
other. The patient with IPF had a stage 4 adenocarcinoma and
died 1 week after the transplant. The other three had stage 1
disease and survived for a minimum of a year.21 The Toronto
lung transplant group reported six patients with bronchogenic
carcinoma in the explanted lung. Three of the six patients
died within 35 months after transplant, whereas one patient
with lymphangitic carcinomatosis died of bronchiolitis
obliterans 10 months after surgery with no evidence of
recurrence.22 However, the staging of these patients was
incomplete.
An international survey involving 67 centers reported
43 patients with primary bronchogenic cancer found in the
explanted lungs on transplantation for emphysema and pul-
monary fibrosis. Not surprisingly, the 5-year and 10-year sur-
vival of patients with stage 1 disease was much better than
patients with stage 2 or stage 3 disease. Sixty-four percent of
patients with stage 1 disease were alive after a median follow-up
of 30 months posttransplantation, whereas 64% of stage 2 and 3
patients were dead from recurrence after 8 months.23
From these reports, although small in number, it is clear
that patients who are found to have stage 1 non-small cell
lung cancer (NSCLC) in the explanted lung have a much
better chance of recurrence-free survival compared with those
that have stage 2 or 3 disease. The practice of doing com-
puted tomography (CT) scans of the chest in some centers
before the transplant procedure is likely to bring the number
of such cases down but will not totally eliminate them.24 Even
during the actual surgery, the lung tumor may not be evident
on examination of the gross specimen, precluding mediastinal
node sampling for full staging. In multiple instances in the
series mentioned earlier, the tumor was noted on pathologic
study postoperatively. As patients wait for lung transplan-
tation attention and follow-up to changes in periodic im-
aging studies would be prudent. At present, there are no
data regarding adjuvant therapy in these patients. Adjuvant
chemotherapy should be administered as appropriate after
a full staging work up as would be done for nontrans-
planted patients.
Bronchogenic Carcinoma of Donor Origin
In contrast to the many reports of lung cancer in native
lungs of transplant patients, reports of primary lung cancer in
donor lungs are scarce. A 25-year-old patient with cystic
fibrosis who received a bilateral lung transplant from a
50-year-old former smoker presented with metastatic small
cell lung cancer 13 months after transplant. He was treated
with standard chemotherapy with no clinical response and
died a month later. Molecular genetic analysis confirmed the
donor origin of the malignancy.25 Likewise, a 54-year-old
woman with end-stage COPD and a 100-pack-year smoking
history who underwent a bilateral lung transplant from a
55-year-old woman with a 45-pack-year smoking history
developed a stage 2A moderately differentiated adenocarci-
noma of the lung 28 months after the transplant. Cytogenetic
analysis confirmed the donor origin of the cancer. The patient
did well after surgical resection.26 In addition to these two
patients, a 25-year-old woman, nonsmoker with cystic fibro-
sis who received sequential bilateral lung transplants from a
male donor, was reported to have limited stage small cell lung
cancer in the transplanted lung. The origin of the cancer from
the recipient was confirmed by fluorescence in situ hybrid-
ization for chromosomes X and Y.27
The very rare occurrence of primary lung cancers in the
transplanted lung is probably because of the younger age and
nonsmoker status of the donors in the early lung transplant
program. With the acceptance of donors who are older and
with a history of smoking, together with the longer survival
of recipients primary lung cancers of donor origin may
increase with time.
TABLE 2. Smoking History and Time to Diagnosis in
Retrospective Studies of Lung Transplant Patients with Lung
Cancer in the Native Lung
Author
Indication for
Transplant in
Patients Who
Developed Cancer
Smoking
History
Mean Time to
Diagnosis from
Transplant (Range)
Spiekerkoetter
et al.9
NA NA 37.3 mo (5–71)
Choi et al.10 IPF (1/1) 1/1 4 mo
Arcasoy et al.11 COPD (5/6) 6/6 15 mo (0–60)
IPF (1/6)
Collins et al.13 Emphysema (18/21) 19/21 34 mo (NA)
IPF (3/21)
de Perrot et al.12 Emphysema (1/1) 0/1 9 mo
Dickson et al.14 Emphysema (8/9) 9/9 52.3 mo (NA)
IPF (1/9)
NA, not available; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive
pulmonary disease.
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Bronchioalveolar Carcinoma and Lung
Transplantation
Bronchioloalveolar carcinoma (BAC) with intrapulmo-
nary metastasis has been treated in some centers with lung
transplantation. In general, these patients are younger and
many have a limited smoking history. In addition, the ten-
dency of BAC not to spread as rapidly outside the lungs but
rather presenting with intrapulmonary metastasis has been
thought to make it a suitable disease for attempts at cure by
lung transplantation.28 Garver et al. reviewed seven patients
who had disease confined to lungs and received single or
bilateral lung transplants with the intent of achieving a
curative resection. Four patients had recurrent disease after a
prior resection and three had stage 4 disease. Four of the
seven recurrences occurred within the donor lung within 10 to
48 months from transplantation. The presentation of recurrent
disease in the donor lung so soon after transplantation raises
a variety of interesting questions regarding pathogenesis
including the intriguing possibility of an infectious etiology
for cancer in these patients. All the recurrences were identi-
fied as of recipient origin by polymerase chain reaction of
microsatellite DNA.29 This cohort of patients has a 52%
5-year survival that did not differ significantly from the
survival rates in their total lung transplant population. It
seems that lung transplantation may be of palliative value in
selected patients in view of the prolongation of life and relief
of symptoms.30 An international survey identified 26 patients
who received lung transplants for BAC from 67 centers. The
5-year and 10-year survival was 39 and 31%, respectively.
The recurrence-free survival at 5 years was 35% and the
median time of recurrence was 12 months from transplanta-
tion. The site of recurrence was always pulmonary raising the
possibility of reresection with curative intent if detected early
enough.23 Nevertheless, lung transplant for advanced BAC is
currently performed only in a few centers.
Possible Etiology of Lung Cancer in the
Transplant Setting
A malignancy occurring in an immunosuppressed pa-
tient raises the possibility of an infectious etiology. Recur-
rences of BAC have been reported in the healthy donor lung
within just several years after implantation.29 Malignant
transformation mediated by a viral oncogene is a tantalizing
possibility when lung cancer occurs in the context of lung
transplantation and immunosuppression. Oncogenic viruses
have long been known.31 For example, HTLV-1 and HTLV-2
cause T-cell leukemia in humans.32 In thoracic cancers, the
connection between cancer and infectious etiologies remains
somewhat more tenuous. Jaagsiekte sheep retrovirus causes
pulmonary adenocarcinoma in sheep resembling human ad-
enocarcinoma of the lung.33 Simian virus 40-related DNA
sequences have been detected in mesotheliomas and NSCLC;
however, an etiologic role has been difficult to prove.34
Condylomatous changes noted in NSCLC similar to human
papillomavirus (HPV)-induced genital lesions raised the pos-
sibility of HPV infection as a risk factor for developing
cancer in the 1980s.35 An increased incidence of lung cancer
in survivors of cervical cancer treated with radiation has also
been noted raising the possibility of an association with HPV,
a strong etiological factor for cervical cancer.36 Overall,
about 20% of all lung cancers tested contain HPV DNA,
mostly in squamous cell carcinomas. The most common
serotypes found were HPV16 and 18, which are strongly
associated with cervical cancer.35 The viral E6 protein has
been shown to be expressed in HPV16-infected lung adeno-
carcinoma cell lines, reinforcing the idea that HPV infection
could be a cofactor in lung cancer development.37 However,
HPV infection has not yet been shown to cause malignant
transformation in normal lung tissue. The frequency of HPV
viral DNA detection in lung cancers from transplanted pa-
tients is unknown. A viral etiology for posttransplant lung
cancer remains purely speculative.
Lung cancer occurring in the context of scarring was
described several decades ago.38,39 The etiology of these
“scar carcinomas” is usually connected to previous tubercular
infection. A similar association with scarring because of
histoplasmosis has been suggested by a pathologic study of
T1 cancers.40 Case–control studies have shown an elevated
odds ratio for lung cancer in patients with a history of
previous pulmonary tuberculosis.41 An inflammatory re-
sponse to recurring or chronic infections may be the key to
the development of these lung cancers.42 Whether chronic
infection and inflammation has a role in developing lung
cancer in lung transplant recipients is not known but remains
an intriguing possibility.
The obvious etiological factor for the development of
malignancies in patients after organ transplantation is immu-
nosuppresion. In the 1980s, the introduction of cyclosporine
allowed increased numbers of successful lung transplants.
The majority of the patients were maintained on a triple drug
combination of a calcineurin inhibitor (cyclosporine), cell
cycle inhibitor (azathioprine), and steroids.43 Tacrolimus,
which was introduced in the 1990s, is being increasingly used
in immunosuppression in lung transplant recipients because
of a decreased incidence of acute rejection.44
There is little data in lung transplant patients comparing
the incidence of lung cancer in the different immunosuppres-
sive regimens. A group from Spain reported 10 patients
among 129 lung transplant patients who developed different
malignancies. They did not find a significant difference in the
use of induction with basiliximab (chimeric mouse monoclo-
nal antibody to IL-2R) in the patients who developed
malignancy versus the patients without malignancy.45
Sirolimus (rapamycin) a macrocycline lactone was ini-
tially used in lung transplantation to rescue patients in chronic
rejection.46 Sirolimus-based regimens seem to be associated
with a less incidence of malignancy in renal transplant pa-
tients compared with other regimens in a transplant registry.47
Conversion to sirolimus-based immunosuppressive regimens
have been noted to cause regression of Kaposi sarcoma and
posttransplant lymphoproliferative disease (PTLD) in renal
transplant patients with acceptable side effects.48,49 A similar
strategy has been reported in Kaposi sarcoma in lung trans-
plant patients.50 Sirolimus has been shown to reduce the
growth and metastasis of murine and human NSCLC cell
lines injected subcutaneously in a mouse model.51 Conver-
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sion of the immunosuppressive regimen to one based on
sirolimus in lung transplant patients diagnosed to have lung
cancer is a strategy that may have positive effects in terms of
inhibiting the growth of the tumor. We do note a case series
of 29 patients with different malignancies after renal trans-
plantation who had calcineurin inhibitors withdrawn and a
sirolimus-based regimen initiated. Of the six enumerated lung
cancer patients, at least two progressed to metastasis at the
time of the report.52
The recipient origin of bronchioalveolar cancers in
Garver et al. indicates that there is some amount of chimerism
of the cells in the transplanted lung as discussed by the
author. It is unclear at this point whether the migration of
recipient’s cells into the transplanted lung is hematogenous
from a source of stem cells like the bone marrow or a
migration of cells along the airways.29 Myelosuppression has
been shown to accentuate bleomycin-induced lung injury in
mice. Bone marrow-derived mesenchymal stem cells trans-
ferred to the injured mouse was shown to migrate to the
injured lung and be protective.53 Hematogenous spread of
stem cells has important implications for the hope of
preventing lung cancer by bilateral lung transplantation,
because even after bilateral lung transplantation there is
the possibility of cancer recurrence through implantation
of circulating stem cells.
Most of the reported lung cancers after lung transplan-
tation were in the recipient’s native lung that was left in situ.
(Table 1). The study by Dickson et al. compared 131 con-
secutive single lung transplant patients with 131 consecutive
bilateral lung transplant patients matched by native disease.
There were nine single lung transplant patients who devel-
oped primary lung cancer in the recipient’s native lung,
whereas none of the matched bilateral lung transplant patients
developed lung cancer.14 This raises the question whether a
bilateral lung transplant will be more beneficial to the patient.
Whether bilateral lung transplantation is superior to single
lung transplantation has been studied for many years. Signif-
icantly, better forced expiratory volume in the first second,
single breath diffusing capacity, and arterial oxygen tension
were noted in the bilateral transplantion group compared with
the single lung transplantation group.54 Initial studies did not
show a significant advantage of bilateral lung transplantation
in terms of survival.55 Single lung transplants had an advan-
tage because of the scarcity of donated organs. Meyer et al.
reported on the long-terms survival advantage for patients
less than 60 years with COPD.56 The number of bilateral lung
transplantations exceeded single lung transplantations by
2002 and accounted for 63% of the procedures performed in
2005. Survival after bilateral lung transplantation was signif-
icantly better compared with single lung transplantation in
COPD and IPF.57 At present, there is insufficient data to predict
how this shift to bilateral lung transplantation will impact the
presentation of lung cancer in lung transplant patients. The
impact of the increased proportion of bilateral lung transplanta-
tion is likely to be felt over the next few years.
Diagnosis
All lung transplant patients are followed with frequent
chest radiographs immediately after transplant. Imaging be-
comes less frequent with time. The diagnosis of lung cancer
was based on the radiologic finding of a new or enlarging
nodule or mass in asymptomatic patients in the majority of
cases reported.10 On the other hand, the majority of nodules
and masses noted in transplant patients tend to be of infec-
tious origin. Schulman et al. found 15 patients with new
nodules or masses out of 159 patients who survived the first
3 months after transplant in a mean follow-up period of 32
months. Ten were of infectious origin; the other five con-
sisted of two lymphomas, two lung cancers, and one lung
infarct.58 After reviewing 234 lung transplants from 1990 to
2000, Lee et al. also concluded that the majority of the
pulmonary nodules discovered after lung transplant were due
to infectious causes or PTLD. They found solitary nodules to
be due to lung cancer or PTLD, whereas multiple nodules
were due to infectious causes.59
In retrospective reviews, it has been noted that the
lesion that was finally biopsied to prove malignancy was
actually present in previous radiographs in certain pa-
tients.9,60 This is particularly notable in patients who have
single lung transplants for COPD and IPF. The scarring and
nodularity in the native lung may conceal the radiologic
changes that would raise the suspicion of lung cancer. Be-
cause of this, these tumors may present at a more advanced
stage. End et al. noted that 8 of 64 patients developed
pulmonary nodules in a median follow-up period of 5.8
months. They recommended surveillance CT scans as routine
follow-up every 3 to 6 months because some lesions maybe
missed on chest radiograph.61 In 2002, the University of
Texas Southwestern Medical Center in Dallas, Texas, insti-
tuted a protocol for annual screening chest CT protocol for all
heart transplant patients with a smoking history greater than
10 pack-years. All four patients identified by CT scans were
resectable compared with 6 of 16 patients with lung cancer
identified by chest radiograph. The authors recommended
“routine” chest CT scans for high-risk patients with signifi-
cant smoking history.62 Similarly, a French group recom-
mended twice yearly combined chest radiographs and chest
CT scans to detect lung cancer early in heart transplant
patients.63 It may be legitimate to extrapolate the experience
with heart transplant patients to lung transplant patients and
recommend once or twice yearly chest CT scans to detect
lung cancer early at a resectable stage. A strong recommen-
dation is to work up all nodules and masses seen in transplant
patients until a definite histologic diagnosis is made. If
suspicion for malignant pathology remains, periodic chest CT
is advisable considering the seriousness of an infectious or
malignant etiology.
PET scans and combined CT/PET scans are attractive
as a mode to help in distinguishing whether nodules are likely
to be malignant. However, it is difficult to conclude that PET
scans give unequivocal proof of malignancy without a tissue
diagnosis. PET scans have utility in distinguishing infections
from rejection, but in addition there is a modest PET uptake
that is noted even in asymptomatic lung transplant patients
without infection or rejection.64 PET scans have been shown
to be useful in the diagnosis of PTLD in solid organ trans-
plant patients including lung.65,66 The reports however are
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limited by the small number of patients and by not being
prospective in nature. Although there is dearth of data ad-
dressing the utility of PET scans in lung transplant patients
suspected of having lung cancer; it would be legitimate to
conclude that PET scans, although likely to be helpful in
diagnosis and staging, cannot be a substitute for obtaining a
tissue biopsy. In any case, PET positivity of a nodule in the
lung of a transplant patient merits further work up.
CT-guided transthoracic biopsy of the lung has been
shown to have a high sensitivity and nearly 100% specificity.67
Transthoracic needle biopsy has been used to evaluate for
rejection in lung transplant patient with acceptable sensitivity
and specificity.68 Diagnostic accuracy increases with the
number of biopsies taken from a nodule.69 Transthoracic
needle biopsy can be associated with significant morbidity. In
a report on eight patients with severe emphysema who had
CT-guided transthoracic biopsy done to work up lung nodules
before transplantation, six developed pneumothorax with four
requiring chest tubes.70 Considering the already compromised
lung function in lung transplant patients, transthoracic biop-
sies need to be approached with sufficient caution. Fiber optic
bronchoscopy with multiple transbronchial biopsies have
been used successfully in lung transplantation patients to
evaluate for rejection and infection.71 This is another modal-
ity that can be used to obtain a tissue diagnosis where the
imaging studies are suspicious for malignancy in lung trans-
plant patients. If suspicion for malignancy remains after
unsuccessful or inconclusive attempts at biopsy, periodic
chest CT to monitor the progression of the nodule is advisable
considering the seriousness of an infectious or malignant
etiology.
Treatment
Individualizing treatment decisions for lung transplant
patients are complicated by several contending factors. The
functional capacity is rarely optimum, the respiratory reserve
may already be low because of the underlying disease, and
there maybe ongoing issues with renal insufficiency and
infection. Chemotherapeutic agents may interact with the
patient’s immunosuppressive agents. A retrospective review
regarding the management of 17 lung cancer patients who
were heart and lung transplant recipients reported a median
overall survival of 12 months. No patient with stage 2, 3, or
4 disease survived more than a year after diagnosis. The
5-year survival of patients with stage 1 disease was 35%.
Eleven patients had stage 1 or 2 disease; two patients with
resectable disease were poor surgical candidates and were
treated with radiation therapy. The majority of patients pre-
sented with incidental radiographic findings regardless of
clinical stage.72 Considering the disappointing treatment re-
sults in advanced lung cancer in the transplant setting, atten-
tion should be focused on detecting the tumor at an early
stage when it can be resected.
The number of lung cancers in solid organ transplant
patients requiring adjuvant chemotherapy that have been
reported are few, making it difficult to draw clear conclu-
sions. It is instructive to note that 3 of 10 renal transplant
patients with invasive breast cancer who were offered adju-
vant chemotherapy elected not to have adjuvant chemother-
apy because of concerns regarding the viability of the renal
graft. Of the five individuals who underwent chemotherapy,
the four who had functioning grafts did not develop transplant
failure or renal insufficiency.73 Decision making for chemo-
therapy for lung cancer in lung transplant patients is likely to
be more complicated, considering the different response of
NSCLC to chemotherapy compared with breast cancer and
the different chemotherapy regimens used for lung cancer,
especially the platinum compounds which are more likely to
cause renal insufficiency. Chemotherapy in lung transplant
patients is also likely to be more risky in terms of opportu-
nistic infections because the lungs are in constant contact
with the external environment. A study on heart transplant
patients who underwent surgery for lung cancer reported that
7 of the 25 patients had postoperative infectious complica-
tions and three patients died in the postoperative period.63
A careful reduction in immunosuppression and a
change of the immunosuppression to sirolimus are promising
strategies that need to be specifically investigated in lung
cancers in lung transplant patients. Prospective studies pool-
ing patients from multiple centers internationally are required
to obtain sufficient data to make cogent recommendations
about treatment strategies in these patients.
CONCLUSION
Bronchogenic carcinoma in lung transplant patients is
uncommon but likely to become more frequent with the
changing demographics of lung transplantation. This is most
likely to be a NSCLC of recipient origin in the native lung. A
history of smoking, COPD, IPF, and advanced age of either
recipient or donor seem to be risk factors for developing a
posttransplant lung cancer. Screening prospective donors with a
smoking history with a CT scan of the chest may reduce this
risk. An early diagnosis is important because treatment outcome
of advanced disease is disappointing.
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